Context Therapeutics announced its 2025 financial results and progress in developing T cell-engaging bispecific antibodies for solid tumors. The company expects to release interim Phase 1a data for its CTIM-76 trial in June 2026 and for CT-95 in September 2026, with a Phase 1 trial for CT-202 starting in Q3 2026. With $66 million in cash at year-end 2025, Context anticipates funding operations into mid-2027, supporting ongoing clinical development and multiple updates throughout 2026. The company reported a net loss of $36.1 million for 2025, reflecting increased research and development expenses as it advances its pipeline.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
